Pfizer offers patent-protected medicines on not-for-profit to 45 low income countries
Pfizer calls upon global health leaders and organizations to join the Accord, bringing their expertise and resources to close the health equity gap
Pfizer calls upon global health leaders and organizations to join the Accord, bringing their expertise and resources to close the health equity gap
The company will invest approximately €440 million to increase membrane manufacturing capacity in Carrigtwohill and to build a new manufacturing facility at Blarney Business Park, both in Cork, Ireland
Includes thermostabilized Ebola vaccines
Pharmapack Europe recognizes excellence and innovation from exhibitors across connected devices, sustainability, supply chain logistics, route of administration, and packaging innovation, as well from the wider industry for patient-centric design and eco-design
The vaccine was found to have 64% efficacy against symptomatic disease and 92% against severe Covid-19
Children 5 through 11 years of age are now authorized to receive a booster dose at least five months after the second dose of the two-dose primary series
Viralex (Inosine Pranobex) is an immunomodulatory agent with broad-spectrum antiviral properties
The move comes a few weeks after receiving the EUA for children between the ages of 5 and 12
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
The licences will allow manufacturers from around the world to work with MPP and C-TAP to make these technologies accessible to people living in low- and middle-income countries
Subscribe To Our Newsletter & Stay Updated